Despite Negative New York Times Article "Dubius Cardiac", Jefferies Maintains Buy on HCA Inc (HCA)

Article Stock Quotes (1) Comments (0)

A DOJ inquiry and newly released New York Times article discussing "dubious cardiac" clinical and billing practices at HCA Inc (NYSE: HCA) has added a new overhang to this stock, thinks Arthur Henderson, an analyst at Jefferies.

"However, as prospects for another special dividend grow, these anxieties will abate, and the stock will likely move higher," said Henderson.

Jefferies has a Buy rating on HCA Holdings (NYSE: HCA). They firm lowered the price target to $30.00 (from $34.00) to reflect overhangs.

For an analyst ratings summary and ratings history on HCA Holdings click here. For more ratings news on HCA Holdings click here.

Shares of HCA Holdings closed at $25.55 yesterday, with a 52 week range of $17.03-$31.39.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
• Hewlett-Packard (HPQ) Q2 Performance Wins Praise on Wall Street; Jefferies Raises to Hold
• Bulls and Bears Do Battle in Aeropostale (ARO); Turnaround Intact?

Create E-mail Alert Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co, Dividend

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?